BR9609853A - Estruturas com manifestação de p16 e sua aplicação na terapia de c‰ncer. - Google Patents

Estruturas com manifestação de p16 e sua aplicação na terapia de c‰ncer.

Info

Publication number
BR9609853A
BR9609853A BR9609853-8A BR9609853A BR9609853A BR 9609853 A BR9609853 A BR 9609853A BR 9609853 A BR9609853 A BR 9609853A BR 9609853 A BR9609853 A BR 9609853A
Authority
BR
Brazil
Prior art keywords
structures
manifestation
cancer therapy
application
expression
Prior art date
Application number
BR9609853-8A
Other languages
English (en)
Inventor
Xiaomei Jin
Jack Roth
Original Assignee
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas filed Critical Univ Texas
Publication of BR9609853A publication Critical patent/BR9609853A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

"ESTRUTURAS DE MANIFESTAçãO DE p16 E SUA APLICAçãO NA TERAPIA DO C‰NCER". Uma variedade de estruturas genéticas são reveladas e que encontrarão uso in vitro e in vivo na área da biologia tumoral e na terapia do câncer. Em particular, provê-se estruturas de manifestação que contêm uma região que codifica p16 e outros elementos reguladores necessários à manifestação de um transcrito de p16. Uma versão da estrutura de manifestação é um vetor adenoviral réplico-deficiente. Também se provê métodos para a transformação de linhas de células e para a inibição da proliferação de células cancerosas.
BR9609853-8A 1995-07-17 1996-07-17 Estruturas com manifestação de p16 e sua aplicação na terapia de c‰ncer. BR9609853A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50288195A 1995-07-17 1995-07-17
PCT/US1996/011787 WO1997003635A2 (en) 1995-07-17 1996-07-17 p16 EXPRESSION CONSTRUCTS AND THEIR APPLICATION IN CANCER THERAPY

Publications (1)

Publication Number Publication Date
BR9609853A true BR9609853A (pt) 1999-10-13

Family

ID=23999797

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9609853-8A BR9609853A (pt) 1995-07-17 1996-07-17 Estruturas com manifestação de p16 e sua aplicação na terapia de c‰ncer.

Country Status (15)

Country Link
US (1) US6251871B1 (pt)
EP (1) EP0839207A2 (pt)
JP (1) JPH11510380A (pt)
KR (1) KR19990029028A (pt)
CN (1) CN1203632A (pt)
AU (1) AU724324B2 (pt)
BR (1) BR9609853A (pt)
CA (1) CA2227193A1 (pt)
CZ (1) CZ15498A3 (pt)
HU (1) HUP9901908A3 (pt)
NO (1) NO980218L (pt)
NZ (1) NZ313828A (pt)
PL (1) PL324750A1 (pt)
SK (1) SK6598A3 (pt)
WO (1) WO1997003635A2 (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6689561B1 (en) * 1994-04-14 2004-02-10 The Regents Of The University Of California Tumor suppressor gene and methods for detection of cancer, monitoring of tumor progression and cancer treatment
US7163925B1 (en) * 1995-07-17 2007-01-16 Board Of Regents, The University Of Texas System p16 expression constructs and their application in cancer therapy
GB9519275D0 (en) 1995-09-21 1995-11-22 Univ Dundee Substances and their therapeutic use
EP0862445B2 (en) † 1995-10-06 2017-03-22 Arch Development Corporation Combination of herpes simplex virus and chemotherapy for treating cancer
JP2001524812A (ja) * 1997-02-20 2001-12-04 ヘパヴェック アクチエンゲゼルシャフト フール ジェンセラピー アポトーシス誘導タンパク質に対するｒｂの比率の減少による悪性細胞におけるアポトーシス細胞死の誘導方法
DE69830304T2 (de) 1997-03-14 2005-10-20 Unilever N.V. Gefrierschutzpeptide enthaltendes gefrorenes produkt
US6489305B1 (en) 1998-05-08 2002-12-03 Canji, Inc. Methods and compositions for the treatment of ocular diseases
KR19990086165A (ko) * 1998-05-26 1999-12-15 성재갑 Cdk４ 의 저해제인 p16의 카복시말단이 절단된 결손형cδp１６ 단백질, 그의 유전자
US6420345B1 (en) * 1999-03-01 2002-07-16 Cell Genesys, Inc. Methods and reagents for inhibiting angiogenesis
US20040266834A1 (en) * 1999-10-14 2004-12-30 Copland John A. Thiazolidinediones alone or in cabination with other therapeutic agents for cancer therapy
AU2001278981A1 (en) * 2000-07-21 2002-02-05 Tom F Lue Prevention and treatment of sexual arousal disorders
US7223406B2 (en) * 2000-07-21 2007-05-29 The Regents Of The University Of California Methods and compositions for preventing and treating male erectile dysfunction and female sexual arousal disorder
US20040005294A1 (en) * 2002-02-25 2004-01-08 Ho-Young Lee IGFBP-3 in the diagnosis and treatment of cancer
US20030219696A1 (en) * 2002-05-23 2003-11-27 Moreland Gerald W. Method and apparatus for preventing backflow in dental saliva evacuators
NZ546983A (en) 2003-11-24 2009-05-31 Canji Inc Reduction of dermal scarring
PL1799230T3 (pl) 2004-08-27 2013-05-31 Cyclacel Ltd Purynowe i pirymidynowe inhibitory CDK i ich zastosowanie do leczenia chorób autoimmunologicznych
US7695965B2 (en) * 2006-03-02 2010-04-13 Cythera, Inc. Methods of producing pancreatic hormones
CN103293308B (zh) * 2013-05-24 2014-11-26 尉军 一种检测肿瘤标志物p16抗原表位氨基酸序列及应用
CN104558147B (zh) * 2015-01-20 2017-11-07 刘林林 一种检测宫颈癌标志物cdkn2a抗原表位多肽及应用
AU2016262631A1 (en) 2015-05-14 2017-11-30 Expression Pathology, Inc. SRM/MRM assay for the fibroblast growth factor receptor 2 (FGFR2) protein
CA2986730C (en) 2015-05-22 2020-04-14 Expression Pathology, Inc. Srm/mrm assay for the cyclin-dependent kinase inhibitor 2a (p16) protein

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0273085A1 (en) 1986-12-29 1988-07-06 IntraCel Corporation A method for internalizing nucleic acids into eukaryotic cells
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5747469A (en) 1991-03-06 1998-05-05 Board Of Regents, The University Of Texas System Methods and compositions comprising DNA damaging agents and p53
US6211334B1 (en) 1992-10-16 2001-04-03 Cold Spring Harbor Cell-cycle regulatory proteins, and uses related thereto
JP3485186B2 (ja) 1992-10-16 2004-01-13 コールド・スプリング・ハーバー・ラボラトリー サイクリン複合体の転位およびそれに関連する使用
FR2705686B1 (fr) 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
MY119195A (en) * 1993-12-30 2005-04-30 Shell Int Research Lightweight, wide-bodied compliant tower.
AU685627B2 (en) 1994-03-18 1998-01-22 Myriad Genetics, Inc. Germline mutations in the MTS gene and method for detecting predisposition to cancer at the MTS gene
CN1128935A (zh) 1994-03-18 1996-08-14 亿万遗传股份有限公司 多肿瘤抑制因子基因、其突变和用该基因序列诊断癌肿的方法
US6689561B1 (en) * 1994-04-14 2004-02-10 The Regents Of The University Of California Tumor suppressor gene and methods for detection of cancer, monitoring of tumor progression and cancer treatment
EP0758382A1 (en) 1994-04-29 1997-02-19 Sidney Kimmel Cancer Center Enhancing the sensitivity of tumor cells to therapies
DE19501073A1 (de) * 1995-01-16 1996-08-01 Nova C O R D Ag Bildverarbeitungsverfahren zur Ermittlung der Strukturfestigkeit eines Prüfobjektes mit diffus streuender Oberfläche
AU5297496A (en) * 1995-02-17 1996-09-04 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Methods of preparation and use of recombinant adenoviral vectors
US5672508A (en) 1996-01-23 1997-09-30 Mitotix, Inc. Inhibitors of cell-cycle progression, and uses related thereto
CA2282683A1 (en) 1997-02-18 1998-08-20 Canji, Inc. Combined tumor suppressor gene therapy and chemotherapy in the treatment of neoplasms

Also Published As

Publication number Publication date
KR19990029028A (ko) 1999-04-15
NO980218D0 (no) 1998-01-16
US6251871B1 (en) 2001-06-26
CN1203632A (zh) 1998-12-30
NZ313828A (en) 1999-02-25
WO1997003635A3 (en) 1997-05-15
NO980218L (no) 1998-03-16
JPH11510380A (ja) 1999-09-14
HUP9901908A2 (hu) 1999-09-28
CZ15498A3 (cs) 1998-07-15
HUP9901908A3 (en) 2000-02-28
PL324750A1 (en) 1998-06-08
AU6647896A (en) 1997-02-18
WO1997003635A2 (en) 1997-02-06
AU724324B2 (en) 2000-09-14
EP0839207A2 (en) 1998-05-06
SK6598A3 (en) 1998-09-09
CA2227193A1 (en) 1997-02-06

Similar Documents

Publication Publication Date Title
BR9609853A (pt) Estruturas com manifestação de p16 e sua aplicação na terapia de c‰ncer.
BR9809846A (pt) Método para produzir um adenovìrus deficiente em replicação
BR9612677A (pt) Sistemas complementares de vetores adenovírais e linhagens celulares
FI951138A (fi) Puuttellisia adenovirusvektoreita ja niiden käyttö geeniterapiassa
DE69634752D1 (de) Adenovirale vektoren beinhaltend ein prostata spezifisches antigen (psa) "response element"
NO179615C (no) Monoklonale antistoffer eller fragmenter derav som reagerer med kakektin, cellelinjer som produserer dem, prövesett som omfatter dem, samt anvendelse derav in vitro
BR0014087A (pt) Composições com pérolas de caroteno - xantofila estáveis e métodos de uso
BR9812384A (pt) Produtos revestidos
DE97905729T1 (de) Als 2f1 bezeichnetes rezeptorprotein
ES2191749T3 (es) Utilizacion de aerogeles inorganicos en farmacia.
DE69830251D1 (de) Langes pentraxin ptx3 enthaltende pharmazeutische zusammensetzungen
ATE255632T1 (de) Immortalisierung bzw. desimmortalisierung von zellen
NO982874L (no) Farmasöytiske preparater med vitamin D-analoger
DK1135513T4 (da) Adenovirus-medieret genterapi
FI930050A (fi) Foerfarande foer finfoerdelning av konstmaterial eller organiska naturliga polymerer
AU7423391A (en) Dna constructs for the expression of proteins in the mammary gland of transgenetic mammals
ES2120667T3 (es) Sal de l-carnitina y composiciones cosmeticas y farmaceuticas que la contienen para tratamiento de dermatosis.
PT952975E (pt) Compostos bi-aromaticos ligados por um radical hetero-etinileno e composicoes farmaceuticas e cosmeticas que os contem
BR9917238A (pt) Aplicador de revestimento lìquido tendo meios para aplicação espaçada
FI960839A (fi) Uusia tripeptidejä, jotka ovat käyttökelpoisia immuuni- ja CNS-terapiassa
IT1230167B (it) Procedimento per il rivestimento con pellicola di composizioni farmaceutiche con dispersioni di polimeri.
DK0925064T3 (da) 5-Androsten-3-beta,17-alpha-diol som inhibitor for tumorvækst
Sutherland et al. Developmental biology and oncology: two sides to the same coin? Sixth International Conference on the Differentiation of Normal and Neoplastic Cells sponsored by the International Society of Differentiation and the Canadian Society for Cellular and Molecular Biology, Vancouver, BC, Canada, July 29-August 2, 1990
EP0843006A3 (en) Recombinant PSA expression vectors and assays using the same
SU640084A1 (ru) Трубопровод

Legal Events

Date Code Title Description
EG Technical examination (opinion): publication of technical examination (opinion)
FC Decision: refusal